---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-043771"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:41:04.253400+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Evommune reports positive Phase 2a top-line data for EVO301 in atopic dermatitis

## Summary
- Primary endpoint met: 99.8% of posterior distribution exceeded 8% improvement threshold vs placebo.
- Frequentist analysis showed p<0.01 at weeks 4, 8, 12; 33% placebo-adjusted EASI reduction at week 12.
- 23% of EVO301 patients achieved vIGA-AD 0/1 at week 12 vs 0% placebo.
- EVO301 well tolerated; no related serious/severe AEs or treatment discontinuations.
- Company plans Phase 2b dose-ranging trial with subcutaneous formulation; evaluating ulcerative colitis.

## SEC filing metadata
- accession: 0001193125-26-043771
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/0001193125-26-043771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-20260210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-043771
- JSON: https://secwatch.observer/filing/0001193125-26-043771.json
- Plain text: https://secwatch.observer/filing/0001193125-26-043771.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.